The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database
Research output: Journal contributions › Journal articles › Research
Standard
The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency : results of the German KIMS database. / Spielhagen, Christin; Schwahn, Christian; Möller, Kristin et al.
In: Growth Hormone and IGF Research, Vol. 21, No. 1, 01.02.2011, p. 1-10.Research output: Journal contributions › Journal articles › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency
T2 - results of the German KIMS database
AU - Spielhagen, Christin
AU - Schwahn, Christian
AU - Möller, Kristin
AU - Friedrich, Nele
AU - Kohlmann, Thomas
AU - Moock, Jörn
AU - Kołtowska-Häggström, Maria
AU - Nauck, Matthias
AU - Buchfelder, Michael
AU - Wallaschofski, Henri
N1 - Copyright © 2010 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.
PY - 2011/2/1
Y1 - 2011/2/1
N2 - Objective: To evaluate the treatment effects of long-term growth hormone (GH) replacement therapy in adults with GH deficiency (GHD) who were followed in KIMS Germany (Pfizer International Metabolic Database), a national surveillance study. Design: The analysis was performed using baseline and long-term data (range: 4-10. years) of 440 consecutively documented patients (216 women and 224 men) with GHD, aged 20 to 49. years, enrolled in KIMS Germany. Serum insulin-like growth factor I (IGF-I), fasting blood glucose, fasting serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) as well as body mass index (BMI), waist circumference (WC) and hip circumference (HC) at baseline and at last visit were studied. Furthermore, QoL-AGHDA score was determined to assess quality-of-life (QoL). Results: The mean dose of GH over all years was 0.41. mg per day in women and 0.37. mg per day in men. IGF-I and IGF-I SDS levels (standard deviation score) increased significantly (p < 0.001) during GH treatment. The QoL-AGHDA score decreased significantly (p < 0.001), indicating long-lasting improvement in QoL. In total cholesterol, LDL-C and fasting blood glucose, no significant changes were found. Only six patients developed type 2 diabetes during follow-up. Females and males similarly increased significantly in BMI, WC and HC. During GH treatment, recurrences of pituitary or central nervous system tumours or further de novo neoplasia were reported in 6 or 11 patients, respectively. The number of the most frequently reported GH treatment-associated adverse events was low. Conclusion: These observational data show long-term beneficial effects of GH replacement therapy on QoL and show no significant effects on total cholesterol, LDL-C or BMI, WC and HC. Additionally, our data indicate that GH replacement therapy in adults is well tolerated.
AB - Objective: To evaluate the treatment effects of long-term growth hormone (GH) replacement therapy in adults with GH deficiency (GHD) who were followed in KIMS Germany (Pfizer International Metabolic Database), a national surveillance study. Design: The analysis was performed using baseline and long-term data (range: 4-10. years) of 440 consecutively documented patients (216 women and 224 men) with GHD, aged 20 to 49. years, enrolled in KIMS Germany. Serum insulin-like growth factor I (IGF-I), fasting blood glucose, fasting serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) as well as body mass index (BMI), waist circumference (WC) and hip circumference (HC) at baseline and at last visit were studied. Furthermore, QoL-AGHDA score was determined to assess quality-of-life (QoL). Results: The mean dose of GH over all years was 0.41. mg per day in women and 0.37. mg per day in men. IGF-I and IGF-I SDS levels (standard deviation score) increased significantly (p < 0.001) during GH treatment. The QoL-AGHDA score decreased significantly (p < 0.001), indicating long-lasting improvement in QoL. In total cholesterol, LDL-C and fasting blood glucose, no significant changes were found. Only six patients developed type 2 diabetes during follow-up. Females and males similarly increased significantly in BMI, WC and HC. During GH treatment, recurrences of pituitary or central nervous system tumours or further de novo neoplasia were reported in 6 or 11 patients, respectively. The number of the most frequently reported GH treatment-associated adverse events was low. Conclusion: These observational data show long-term beneficial effects of GH replacement therapy on QoL and show no significant effects on total cholesterol, LDL-C or BMI, WC and HC. Additionally, our data indicate that GH replacement therapy in adults is well tolerated.
KW - Health sciences
KW - Adult
KW - Body Weights and Measures
KW - Databases, Factual
KW - Dose-Response Relationship, Drug
KW - Dwarfism, Pituitary
KW - Female
KW - Follow-Up Studies
KW - Germany
KW - Hormone Replacement Therapy
KW - Human Growth Hormone
KW - Humans
KW - Hypopituitarism
KW - Insulin-Like Growth Factor I
KW - Male
KW - Middle Aged
KW - Quality of Life
KW - Risk Assessment
KW - Time Factors
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=79951726718&partnerID=8YFLogxK
U2 - 10.1016/j.ghir.2010.10.005
DO - 10.1016/j.ghir.2010.10.005
M3 - Journal articles
C2 - 21093334
VL - 21
SP - 1
EP - 10
JO - Growth Hormone and IGF Research
JF - Growth Hormone and IGF Research
SN - 1096-6374
IS - 1
ER -